Literature DB >> 19833869

TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.

Iga Wegorzewska1, Shaughn Bell, Nigel J Cairns, Timothy M Miller, Robert H Baloh.   

Abstract

Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative diseases that show considerable clinical and pathologic overlap, with no effective treatments available. Mutations in the RNA binding protein TDP-43 were recently identified in patients with familial amyotrophic lateral sclerosis (ALS), and TDP-43 aggregates are found in both ALS and FTLD-U (FTLD with ubiquitin aggregates), suggesting a common underlying mechanism. We report that mice expressing a mutant form of human TDP-43 develop a progressive and fatal neurodegenerative disease reminiscent of both ALS and FTLD-U. Despite universal transgene expression throughout the nervous system, pathologic aggregates of ubiquitinated proteins accumulate only in specific neuronal populations, including layer 5 pyramidal neurons in frontal cortex, as well as spinal motor neurons, recapitulating the phenomenon of selective vulnerability seen in patients with FTLD-U and ALS. Surprisingly, cytoplasmic TDP-43 aggregates are not present, and hence are not required for TDP-43-induced neurodegeneration. These results indicate that the cellular and molecular substrates for selective vulnerability in FTLD-U and ALS are shared between mice and humans, and suggest that altered DNA/RNA-binding protein function, rather than toxic aggregation, is central to TDP-43-related neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833869      PMCID: PMC2762420          DOI: 10.1073/pnas.0908767106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.

Authors:  L Stefanis; K E Larsen; H J Rideout; D Sulzer; L A Greene
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

3.  Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity.

Authors:  P N Leigh; H Whitwell; O Garofalo; J Buller; M Swash; J E Martin; J M Gallo; R O Weller; B H Anderton
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

4.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Catherine Lomen-Hoerth; Thomas Anderson; Bruce Miller
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

Review 5.  Molecular biology of amyotrophic lateral sclerosis: insights from genetics.

Authors:  Piera Pasinelli; Robert H Brown
Journal:  Nat Rev Neurosci       Date:  2006-09       Impact factor: 34.870

6.  A vector for expressing foreign genes in the brains and hearts of transgenic mice.

Authors:  D R Borchelt; J Davis; M Fischer; M K Lee; H H Slunt; T Ratovitsky; J Regard; N G Copeland; N A Jenkins; S S Sisodia; D L Price
Journal:  Genet Anal       Date:  1996-12

7.  Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.

Authors:  Yong-Jie Zhang; Ya-Fei Xu; Casey Cook; Tania F Gendron; Paul Roettges; Christopher D Link; Wen-Lang Lin; Jimei Tong; Monica Castanedes-Casey; Peter Ash; Jennifer Gass; Vijayaraghavan Rangachari; Emanuele Buratti; Francisco Baralle; Todd E Golde; Dennis W Dickson; Leonard Petrucelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-21       Impact factor: 11.205

8.  Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.

Authors:  I A Klement; P J Skinner; M D Kaytor; H Yi; S M Hersch; H B Clark; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

9.  Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies.

Authors:  Lionel M Igaz; Linda K Kwong; Alice Chen-Plotkin; Matthew J Winton; Travis L Unger; Yan Xu; Manuela Neumann; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

Review 10.  Towards the classification of subpopulations of layer V pyramidal projection neurons.

Authors:  Zoltán Molnár; Amanda F P Cheung
Journal:  Neurosci Res       Date:  2006-03-15       Impact factor: 3.304

View more
  313 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

2.  Reversible behavioral phenotypes in a conditional mouse model of TDP-43 proteinopathies.

Authors:  Julio A Alfieri; Natalia S Pino; Lionel M Igaz
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

3.  Neurotoxic effects of TDP-43 overexpression in C. elegans.

Authors:  Peter E A Ash; Yong-Jie Zhang; Christine M Roberts; Tassa Saldi; Harald Hutter; Emanuele Buratti; Leonard Petrucelli; Christopher D Link
Journal:  Hum Mol Genet       Date:  2010-06-08       Impact factor: 6.150

4.  Core features of frontotemporal dementia recapitulated in progranulin knockout mice.

Authors:  N Ghoshal; J T Dearborn; D F Wozniak; N J Cairns
Journal:  Neurobiol Dis       Date:  2011-09-10       Impact factor: 5.996

Review 5.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

Review 6.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

7.  New treatments in amyotrophic lateral sclerosis.

Authors:  Nicholas Maragakis; Jeffrey D Rothstein
Journal:  Neuropsychopharmacology       Date:  2011-01       Impact factor: 7.853

Review 8.  Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.

Authors:  Daisuke Ito; Norihiro Suzuki
Journal:  Neurology       Date:  2011-09-28       Impact factor: 9.910

9.  Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.

Authors:  Radhia Benmohamed; Anthony C Arvanites; Jinho Kim; Robert J Ferrante; Richard B Silverman; Richard I Morimoto; Donald R Kirsch
Journal:  Amyotroph Lateral Scler       Date:  2010-11-12

10.  Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translation.

Authors:  Alyssa N Coyne; Shizuka B Yamada; Bhavani Bagevalu Siddegowda; Patricia S Estes; Benjamin L Zaepfel; Jeffrey S Johannesmeyer; Donovan B Lockwood; Linh T Pham; Michael P Hart; Joel A Cassel; Brian Freibaum; Ashley V Boehringer; J Paul Taylor; Allen B Reitz; Aaron D Gitler; Daniela C Zarnescu
Journal:  Hum Mol Genet       Date:  2015-09-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.